$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx

$aldx Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000119312518244346 Filed on August 09, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2017 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.070M	$2.370M	$1.480M
YoY Change	107.43%	60.14%	1.37%
% of Gross Profit
Research & Development	$7.881M	$6.793M	$3.849M
YoY Change	122.66%	76.49%	35.79%
% of Gross Profit
Depreciation & Amortization	$20.00K	$20.00K	$10.00K
YoY Change	100.0%	100.0%	0.0%
% of Gross Profit
Operating Expenses	$7.881M	$6.793M	$3.849M
YoY Change	122.66%	76.49%	35.79%
Operating Profit	-$10.95M	-$9.166M	-$5.331M
YoY Change	118.27%	71.95%	24.06%
Interest Expense	$28.85K	$26.36K	$26.46K
YoY Change	4.6%	-0.4%	-4.87%
% of Operating Profit
Other Income/Expense, Net	$134.2K	$115.6K	$21.92K
YoY Change	361.49%	427.34%	-473.7%
Pretax Income	-$10.81M	-$9.050M	-$5.310M
YoY Change	116.68%	70.44%	23.2%
Income Tax
% Of Pretax Income
Net Earnings	-$10.81M	-$9.050M	-$5.309M
YoY Change	116.85%	70.48%	23.38%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$515.5K	-$458.0K	-$350.7K
COMMON SHARES
Basic Shares Outstanding	20.97M shares	20.11M shares	15.13M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q3	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$35.10M	$41.70M	$25.80M
YoY Change	-26.72%	61.63%	-20.62%
Cash & Equivalents	$18.01M	$24.61M	$14.61M
Short-Term Investments	$17.10M	$17.10M	$11.20M
Other Short-Term Assets	$1.700M	$1.400M	$500.0K
YoY Change	54.55%	180.0%	66.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$36.85M	$43.07M	$26.34M
YoY Change	-24.89%	63.51%	-19.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$243.5K	$214.7K	$47.98K
YoY Change	540.46%	347.56%	-36.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$100.0K
YoY Change	-100.0%	-100.0%
Total Long-Term Assets	$286.5K	$214.7K	$125.9K
YoY Change	62.15%	70.54%	67.84%
TOTAL ASSETS
Total Short-Term Assets	$36.85M	$43.07M	$26.34M
Total Long-Term Assets	$286.5K	$214.7K	$125.9K
Total Assets	$37.13M	$43.29M	$26.47M
YoY Change	-24.57%	63.54%	-19.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.442M	$802.1K	$762.7K
YoY Change	609.38%	5.17%	-7.36%
Accrued Expenses	$3.746M	$4.159M	$1.039M
YoY Change	148.5%	300.33%	-4.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$465.3K	$349.0K	$310.2K
YoY Change	9.09%	12.5%	0.0%
Total Short-Term Liabilities	$7.654M	$5.310M	$2.112M
YoY Change	216.37%	151.46%	-11.02%
LONG-TERM LIABILITIES
Long-Term Debt	$882.8K	$995.3K	$1.016M
YoY Change	-2.48%	-2.07%	2.39%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$882.8K	$995.3K	$1.016M
YoY Change	-2.48%	-2.07%	2.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.654M	$5.310M	$2.112M
Total Long-Term Liabilities	$882.8K	$995.3K	$1.016M
Total Liabilities	$8.537M	$6.305M	$3.128M
YoY Change	156.78%	101.57%	-7.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$127.9M	-$117.1M	-$87.70M
YoY Change	37.99%	33.51%	29.22%
Common Stock	$156.5M	$154.1M	$111.0M
YoY Change	12.92%	38.75%	14.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$28.60M	$36.98M	$23.34M
YoY Change
Total Liabilities & Shareholders Equity	$37.13M	$43.29M	$26.47M
YoY Change	-24.57%	63.54%	-19.51%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$10.81M	-$9.050M	-$5.309M
YoY Change	116.85%	70.48%	23.38%
Depreciation, Depletion And Amortization	$20.00K	$20.00K	$10.00K
YoY Change	100.0%	100.0%	0.0%
Cash From Operating Activities	-$7.690M	-$6.250M	-$5.310M
YoY Change	63.62%	17.7%	63.38%
INVESTING ACTIVITIES
Capital Expenditures	-$50.00K	-$60.00K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$30.00K	$920.0K	$650.0K
YoY Change	-100.83%	41.54%	-130.95%
Cash From Investing Activities	-$20.00K	$860.0K	$650.0K
YoY Change	-99.45%	32.31%	-130.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$3.200M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.120M	9.030M	-30.00K
YoY Change	-95.83%	-30200.0%	-100.23%
NET CHANGE
Cash From Operating Activities	-7.690M	-6.250M	-5.310M
Cash From Investing Activities	-20.00K	860.0K	650.0K
Cash From Financing Activities	1.120M	9.030M	-30.00K
Net Change In Cash	-6.590M	3.640M	-4.690M
YoY Change	-135.62%	-177.61%	-162.87%
FREE CASH FLOW
Cash From Operating Activities	-$7.690M	-$6.250M	-$5.310M
Capital Expenditures	-$50.00K	-$60.00K	$0.00
Free Cash Flow	-$7.640M	-$6.190M	-$5.310M
YoY Change	62.55%	16.57%	63.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.07
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6937262
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20974920	shares
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14609742
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4159071
CY2018Q2	us-gaap	Assets Current AssetsCurrent	43071299
CY2018Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	36250402
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	154051733
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	802125
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2559
CY2018Q2	us-gaap	Assets Assets	43286042
CY2018Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	17072720
CY2018Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	34075279
CY2018Q2	us-gaap	Cash Cash	5427993
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24605674
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20842198	shares
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20842198	shares
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	20842
CY2018Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	798243
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5310154
CY2018Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0
CY2018Q2	us-gaap	Liabilities Liabilities	6305445
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43286042
CY2018Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	348958
CY2018Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	995291
CY2018Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	2177681
CY2018Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	214743
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1392905
CY2018Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q2	us-gaap	Securities For Reverse Repurchase Agreements SecuritiesForReverseRepurchaseAgreements	17000000
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-117089419
CY2018Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4944854
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1585500	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.86
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3402163	shares
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	36980597
CY2018Q2	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	17075279
CY2018Q2	aldx	Accrued General And Administrative Expense Current AccruedGeneralAndAdministrativeExpenseCurrent	263076
CY2018Q2	aldx	Fair Value Of Warrant Issued FairValueOfWarrantIssued	266000
CY2018Q2	us-gaap	Share Price SharePrice	7.95
CY2017Q4	aldx	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1327103
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7100000
CY2015Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1100000	shares
CY2018Q2	aldx	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	3097752
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1100000	shares
CY2015Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	7.00
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.50
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	211528	shares
CY2015Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	9.33
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12015061
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2236465
CY2017Q4	us-gaap	Assets Current AssetsCurrent	43965766
CY2017Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	41967314
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	139241635
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1000963
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-17831
CY2017Q4	us-gaap	Assets Assets	44174958
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	22923462
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20023337
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19137639	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19137639	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	19138
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	788570
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3353747
CY2017Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0
CY2017Q4	us-gaap	Liabilities Liabilities	4573939
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44174958
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	116319
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1220192
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43262
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1018967
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-99641923
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2246857	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.87
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	39601019
CY2017Q4	aldx	Accrued General And Administrative Expense Current AccruedGeneralAndAdministrativeExpenseCurrent	120792
CY2017Q4	aldx	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	165930
CY2015Q1	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	0.125
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1900000
CY2015Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	211528	shares
CY2015Q1	aldx	Class Of Warrant Or Rights Expire Month Year ClassOfWarrantOrRightsExpireMonthYear	2018-01
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1463330
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3887377	shares
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	10392
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-130362
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2594681
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10404650
	us-gaap	Depreciation Depreciation	19963
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.72
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3208670
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	487240
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	302801
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-907346
	us-gaap	Interest Expense InterestExpense	53301
	us-gaap	Interest Paid Net InterestPaidNet	41642
	us-gaap	Investment Income Interest InvestmentIncomeInterest	80002
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	26701
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1540065
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10553357
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9498741
	us-gaap	Net Income Loss NetIncomeLoss	-10399881
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4769
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10426582
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4769
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	9270343
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11592
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10585744
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	45555
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	10822000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7217912
	us-gaap	Share Based Compensation ShareBasedCompensation	1463330
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14470555	shares
	aldx	Deferred Offering Costs Paid In Cash DeferredOfferingCostsPaidInCash	77942
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1853199
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3674460	shares
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	7738
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-7163
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4582337
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17432224
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Depreciation Depreciation	29282
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Type DocumentType	10-Q
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.88
	dei	Entity Central Index Key EntityCentralIndexKey	0001341235
	dei	Entity Registrant Name EntityRegistrantName	ALDEYRA THERAPEUTICS, INC.
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4264360
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-198838
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	373938
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1922606
	us-gaap	Interest Expense InterestExpense	54402
	us-gaap	Interest Paid Net InterestPaidNet	46877
	us-gaap	Investment Income Interest InvestmentIncomeInterest	264346
	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="4%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"> <p style="margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;" align="left"><b>NATURE OF BUSINESS</b></p> </td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> Aldeyra Therapeutics, Inc. (the Company or Aldeyra), a Delaware corporation, is developing next-generation medicines to improve the lives of patients with immune-mediated diseases.</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> The Company’s principal activities to date include raising capital and research and development activities.</p> </div>
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	209944
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5658088
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13124533
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14200284
	us-gaap	Net Income Loss NetIncomeLoss	-17447496
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	15272
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17657440
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	15272
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	12091149
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	200763
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13124533
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	17950000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13393080
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.41
	us-gaap	Share Based Compensation ShareBasedCompensation	1853199
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M20D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y11M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1155306	shares
	dei	Trading Symbol TradingSymbol	ALDX
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company’s financial statements relate to accruals, including research and development costs, accounting for income taxes and the related valuation allowance and accounting for stock based compensation and the related fair value. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p> </div>
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19761352	shares
	aldx	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod	0	shares
	aldx	Number Of Incentive Plans NumberOfIncentivePlans	3	Incentive_Plan
	aldx	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice	0
	aldx	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1.00	pure
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	605233
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3887377	shares
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5308653
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1481792
CY2017Q2	us-gaap	Interest Expense InterestExpense	26463
CY2017Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	48384
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	21921
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-5308760
CY2017Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	107
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5330681
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	107
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3848889
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15136399	shares
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	984784
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3674460	shares
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9036609
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2373059
CY2018Q2	us-gaap	Interest Expense InterestExpense	26358
CY2018Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	141956
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	115598
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-9050435
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	13826
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9166033
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	13826
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6792974
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19761352	shares

Files In Submission

Name	View Source	Status
0001193125-18-244346-index-headers.html	Edgar Link	pending
0001193125-18-244346-index.html	Edgar Link	pending
0001193125-18-244346.txt	Edgar Link	pending
0001193125-18-244346-xbrl.zip	Edgar Link	pending
aldx-20180630.xml	Edgar Link	completed
aldx-20180630.xsd	Edgar Link	pending
aldx-20180630_cal.xml	Edgar Link	unprocessable
aldx-20180630_def.xml	Edgar Link	unprocessable
aldx-20180630_lab.xml	Edgar Link	unprocessable
aldx-20180630_pre.xml	Edgar Link	unprocessable
d921331d10q.htm	Edgar Link	pending
d921331dex1029.htm	Edgar Link	pending
d921331dex311.htm	Edgar Link	pending
d921331dex312.htm	Edgar Link	pending
d921331dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g921331g29s66.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx

2018 Q3 Form 10-Q Financial Statement

#000119312518244346 Filed on August 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALDX Aldeyra Therapeutics, Inc. Stock $aldx

2018 Q3 Form 10-Q Financial Statement

#000119312518244346 Filed on August 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx